| Literature DB >> 30158968 |
Ya-Wu Zhang1,2,3, Feng-Xian Wei1,2,3, Xue-Ping Qi3, Zhao Liu4, Xiao-Dong Xu1,2,3, You-Cheng Zhang1,2,3.
Abstract
OBJECTIVES: To evaluate the efficacy and safety of endoscopic intralesional triamcinolone injection (ITI) for benign esophageal strictures combined with endoscopic dilation (ED).Entities:
Year: 2018 PMID: 30158968 PMCID: PMC6109539 DOI: 10.1155/2018/7619298
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Flow chart of trial selection process.
Characteristic of included randomized controlled trials.
| Study | Country | Case (T/C, | Age (T/C, y)∗ | Intervention (T/C) | Dose | Diagnosis | Follow-up (months) | |
|---|---|---|---|---|---|---|---|---|
| T | C | |||||||
| Takahashi et al. 2015 [ | Brazil | 7/7 | 39 (23–64)/46 (22–65) | ED + ITI | ED + saline injection | 40 mg | Corrosive stenosis | 12 |
| Altintas et al. 2004 [ | Turkey | 10/11 | 49 (24–69)/45 (17–76) | ED + ITI | ED | 32 mg | Corrosive, surgical, postradiotherapy | >6 |
| Ramage et al. 2005 [ | USA | 15/15 | 66/67 | ED + ITI | ED | 20 mg | Corrosive esophageal stricture | >12 |
| Hirdes et al. 2013 [ | Netherlands | 29/31 | 64 ± 9/62 ± 8 | ED + ITI | ED + saline injection | 20 mg | Anastomotic stricture | 6 |
| Pereira-Lima et al. 2015 [ | Brazil | 10/9 | 56 ± 8/52 ± 15 | ED + ITI | ED | 40 mg | Anastomotic stricture | 6 |
| Camargo et al. 2003 [ | Japan | 16/16 | 70 ± 10/71 ± 7 | ED + ITI | ED | >30 mg | Endoscopic surgery stricture | >16 |
∗Data were presented as mean ± standard deviation or median (range); T, treatment group; C, control group. ED, endoscopic dilation. ITI, intralesional triamcinolone injection.
Figure 2Summary of methodological quality of included studies.
Figure 3Forest plot of stricture rate between ITI and control.
Figure 4Forest plot of EBD sessions during follow-up between ITI and control.
Figure 5Forest plot of dysphagia-free time between ITI and control.
Figure 6Inverted funnel plot of stricture rate.